X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (18) 18
oncology (15) 15
immunotherapy (14) 14
female (12) 12
male (12) 12
middle aged (12) 12
aged (11) 11
cancer (10) 10
adult (9) 9
care and treatment (9) 9
treatment outcome (7) 7
abridged index medicus (6) 6
article (6) 6
t-lymphocytes, regulatory - immunology (6) 6
tumors (6) 6
blockade (5) 5
colorectal cancer (5) 5
colorectal neoplasms - pathology (5) 5
dendritic cells (5) 5
immunology (5) 5
lymphocytes (5) 5
metastasis (5) 5
pancreatic cancer (5) 5
survival (5) 5
adenocarcinoma (4) 4
aged, 80 and over (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
cancer therapies (4) 4
carcinoma (4) 4
cd8-positive t-lymphocytes - immunology (4) 4
clinical trials (4) 4
disease-free survival (4) 4
health aspects (4) 4
immune checkpoint (4) 4
melanoma (4) 4
neoplasm metastasis (4) 4
poster presentation (4) 4
regulatory t-cells (4) 4
safety (4) 4
animals (3) 3
carcinoma, renal cell - immunology (3) 3
colorectal neoplasms - drug therapy (3) 3
dna repair (3) 3
efficacy (3) 3
hepatocellular carcinoma (3) 3
in-vivo (3) 3
interleukin-2 (3) 3
interleukin-2 - administration & dosage (3) 3
kaplan-meier estimate (3) 3
liver neoplasms - drug therapy (3) 3
long-term survival (3) 3
methods (3) 3
mutation (3) 3
nivolumab (3) 3
patient outcomes (3) 3
patients (3) 3
renal cell carcinoma (3) 3
research (3) 3
surgery (3) 3
usage (3) 3
adoptive immunotherapy (2) 2
analysis (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antigens (2) 2
antigens, neoplasm - immunology (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - adverse effects (2) 2
camptothecin - analogs & derivatives (2) 2
cancer vaccine (2) 2
cancer vaccines (2) 2
cancer vaccines - administration & dosage (2) 2
carcinoma, hepatocellular - drug therapy (2) 2
carcinoma, hepatocellular - immunology (2) 2
carcinoma, hepatocellular - pathology (2) 2
carcinoma, renal cell - therapy (2) 2
cell lung-cancer (2) 2
cells (2) 2
chemotherapy (2) 2
clinical trials as topic (2) 2
colorectal carcinomas (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - surgery (2) 2
colorectal neoplasms - therapy (2) 2
comparative analysis (2) 2
dendritic cell vaccine (2) 2
dna (2) 2
dna mismatch repair (2) 2
dose-response relationship, drug (2) 2
double-blind (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
expressing mesothelin crs-207 (2) 2
expression (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2492 - 2502
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to... 
Internal Medicine | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | IMMUNOTHERAPY | SORAFENIB | BLOCKADE | DOCETAXEL | PD-1 | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Slopes | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Medical services | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety engineering | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2509 - 2520
Persons with mismatch repair–deficient tumors are more likely than persons with mismatch repair–proficient tumors to benefit from pembrolizumab — which... 
MEDICINE, GENERAL & INTERNAL | COLORECTAL CARCINOMAS | ANTI-PD-L1 ANTIBODY | SAFETY | MICROSATELLITE INSTABILITY | DNA | GERMLINE MUTATIONS | PREDISPOSE | CLINICAL ACTIVITY | CANCER | LYMPHOCYTES | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Neoplasm Metastasis - genetics | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | DNA Mismatch Repair | Adult | Female | Adenocarcinoma - genetics | Aged | Colorectal Neoplasms - pathology | Antibody diversity | Carcinoma | Genetic disorders | Analysis | Research | Risk factors | Cancer | Tumors | Antigens | Yeast | PD-1 protein | Colorectal carcinoma | Body weight | Colorectal cancer | Autoantigens | DNA repair | Survival | Metastases | Pembrolizumab | Immune checkpoint | Immunogenicity | Mismatch repair | Death | Mutation | Genetic recombination | Cancer therapies | Drug dosages | Immune system | Medical research | Melanoma | Patients | Studies | Hypotheses | Pancreatic cancer | Epigenetics | Biomarkers | Ligands
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2009, Volume 15, Issue 15, pp. 4986 - 4992
Purpose: To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-α 2a in metastatic renal cell... 
IFN-α | renal cell carcinoma | tumor vaccine therapy | interleukin 2 | dendritic cell vaccine | immunotherapy
Journal Article
Science, ISSN 0036-8075, 07/2017, Volume 357, Issue 6349, pp. 409 - 413
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3649 - 3658
BACKGROUND Reports have demonstrated the superior activity of combining both irinotecan and oxaliplatin (FOLFOXIRI) therapy. An option for gaining similar... 
hepatic artery therapy | liver‐directed therapy | metastatic colon cancer | irinotecan | liver‐dominant metastatic colorectal cancer | liver-directed therapy | liver-dominant metastatic colorectal cancer | CHEMOEMBOLIZATION | RESPONSE EVALUATION | INFUSION | FLUOROURACIL | CANCER | PHASE-II TRIAL | HEPATIC METASTASES | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | SYSTEMIC CHEMOTHERAPY | CARCINOMA | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Delivery Systems - instrumentation | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Hepatic Artery - drug effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Liver Neoplasms - drug therapy | Treatment Outcome | Colorectal Neoplasms - pathology | Drug Delivery Systems - methods | Organoplatinum Compounds - adverse effects | Clinical trials | Care and treatment | Usage | Colon cancer | Diagnosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article